MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...
The Phase 2 ATH434-201 study enrolled 77 adults with MSA who received ATH434 50 mg or 75 mg twice daily, or placebo, for 12 months. The trial evaluated functional outcomes, safety, pharmacokinetics, ...
Two devastating movement disorders, Parkinson’s disease and multiple system atrophy, often look so similar in the clinic that ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
The analysis also showed that a biomarker of disease severity predicted how quickly patients declined. ... Read More The post Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA ...
Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterised by a combination of parkinsonism, cerebellar ataxia and autonomic dysfunction. Clinical assessment ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
In the Phase 2 study, the incidence of treatment-emergent adverse events was similar to placebo, and no unexpected safety signals were identified In mUMSARS scores and MRI-based brain volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results